Journal Article

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Vij, Ravi, Callander, Natalie Scott, Hars, Vera, Schlossman, Robert, Bressler, Linda, Rosenbaum, Cara, Owzar, Kouros, Hari, Parameswaran, Linker, Charles, Bashey, Asad, Bennett, Elizabeth, Landau, Heather, Hassoun, Hani, Stadtmauer, Edward A, Giralt, Sergio, Hofmeister, Craig C, Seiler, Michele, Shea, Thomas C, Hurd, David D, Richardson, Paul G, Qazilbash, Muzaffar H, Gentile, Teresa, Weisdorf, Daniel J, Moreb, Jan S, McCarthy, Philip L, Devine, Steven M, Van Besien, Koen, Pasquini, Marcelo C, McClune, Brian, Maziarz, Richard T, Martin, Thomas, Gabriel, Don A, Barry, Susan, Horowitz, Mary M, Isola, Luis, Jiang, Chen, Kelly, Michael, Levitan, Denise, Anderson, Kenneth C, Postiglione, John

2012

Overview

In patients who had undergone stem-cell transplantation, lenalidomide maintenance therapy improved progression-free and overall survival, though at the expense of some increased hematologic toxicity and second malignant tumors. A goal of therapy for multiple myeloma, to induce complete remission and prolong survival, is usually accomplished with combination therapy. 1 , 2 Autologous hematopoietic stem-cell transplantation is often used after induction chemotherapy to improve the response or to consolidate complete remission. 1 , 2 However, since most patients with multiple myeloma have disease recurrence or progression after transplantation, maintenance therapies have been used to prolong complete remission and prevent relapse or progressive disease. Low-dose melphalan, interferon alfa, and glucocorticoids have been used for maintenance after primary therapy, but their long-term use is limited by toxicity and modest efficacy. 3 – 6 Five studies involving patients who . . .

• Publisher: Massachusetts Medical Society
• Subject: Adult / Aged / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Autografts / Cancer / Cancer therapies / Clinical trials / Disease-Free Survival / Double-Blind Method / Female / Follow-Up Studies / Humans / Immunotherapy / Lenalidomide / Maintenance Chemotherapy / Male / Middle Aged / Multiple myeloma / Multiple Myeloma - drug therapy / Multiple Myeloma - mortality / Multiple Myeloma - therapy / Neoplasms, Second Primary - epidemiology / Stem Cell Transplantation / Targeted cancer therapy / Thalidomide - adverse effects / Thalidomide - analogs & derivatives / Thalidomide - therapeutic use / Toxicity / Transplants & implants